360
Participants
Start Date
May 31, 2008
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
PD 0332334
Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
PD 0332334
Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
Paroxetine
Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
Placebo
Capsules, oral, placebo, BID, 8 weeks with 2 week taper
Pfizer Investigational Site, Tainan City
Pfizer Investigational Site, Budapest
Pfizer Investigational Site, Rochester
Pfizer Investigational Site, Olean
Pfizer Investigational Site, Allentown
Pfizer Investigational Site, Boca Raton
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Bartlett
Pfizer Investigational Site, Dayton
Pfizer Investigational Site, Flint
Pfizer Investigational Site, Flint
Pfizer Investigational Site, Saint Paul
Pfizer Investigational Site, Minneapolis
Pfizer Investigational Site, Park Ridge
Pfizer Investigational Site, Naperville
Pfizer Investigational Site, Prairie Village
Pfizer Investigational Site, New Orleans
Pfizer Investigational Site, DeSoto
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, Houston
Pfizer Investigational Site, Salt Lake City
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Escondido
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, Costa Mesa
Pfizer Investigational Site, Honolulu
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Arcadia
Pfizer Investigational Site, Hamden
Pfizer Investigational Site, Haverhill
Pfizer Investigational Site, Pittsfield
Pfizer Investigational Site, New York
Lead Sponsor
Pfizer
INDUSTRY